

BSL3 HTS Capabilities


- ▶ MTS & HTS screening capabilities for up to 400K compounds in BSL2/BSL2+ & BSL3 laboratories
- ▶ ~200 m² space containing screening equipment adapted for BSL3 pathogen handling, including controlled access, autoclave and H₂O₂ decontamination chamber for liquid and solid waste
- ▶ More than 15 years of screening experience in anti-infectives, including antibacterials and antivirals, with personnel highly trained in working under BSL3 conditions
- ▶ World class centralised compound management platform and 300 m² BSL3 *in vivo* space co-located
- ▶ Support for back screening, hit expansion and progression into hit to lead
- ▶ Access to EvoStrAln a broad collection of clinical isolates and characterised strains (fungi, bacterial, viral and parasitology)

BSL3 Screening Expertise


Bacteria



Virus



Parasite





More than 15 years of screening expertise in anti-infective space, with experience in:

- ▶ Antibacterials (e.g. ESKAPE, Gram positive, *Mycobacterium*, ...)
- ▶ Antivirals (e.g. HBV, HPIV, RSV)
- ▶ Assay development and miniaturisation

Support for back screening, hit expansion, secondary assays for HIT characterisation and progression through hit to lead

Screening capabilities for MTS/HTS

- ▶ Two BSL2/BSL2+ HTS platforms and one BSL2 MTS platform (Agilent workstation)
- ▶ BSL3 lab (~200 m²) including controlled access, autoclave and H₂O₂ decontamination chamber for liquid & solid waste
- ▶ Dedicated team trained in working under BSL3 conditions (HBV, *M.tb*)
- ▶ Basic equipment including adapted safety cabinet, incubators, refrigerators and freezers (-20°C and -80°C)

Automation equipment located within safety cabinet

- ▶ Dispenser for cell/reagent dispensing and plate sealer
- ▶ Pipetor for compound addition
- ▶ Multimode plate reader with stackers

Screening in semi-automatic process (384-well format)



PRROTECT

Leveraging Evotec's pandemic Preparedness and Rapid RespOnse TEChnology plaTform

PRROTECT is a pre-competitive network initiative designed to offer the best protection against future pandemics, including the development and delivery of superior novel therapeutics

Need and opportunity to prepare today for tomorrow's viral pandemics

- ▶ The next global pandemic is certain
- ▶ Integrated pandemic preparedness programs across therapeutic modalities and enhanced antibody development capabilities desired to enable suitable rapid response measures

Evotec is uniquely positioned to develop efficacious next-generation anti-viral drugs

- ▶ Proven expertise and integrated technology platforms for anti-viral drug discovery
- ▶ Multi-modality anti-viral pipeline and antibody technology as differentiated starting points